Boundless Bio, Inc. (Nasdaq: BOLD) and Serapha Bio, Inc., a privately held biotechnology company developing an investigational in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), announce that they have entered into a definitive merger agreement pursuant to which Serapha will combine with Boundless Bio in an all-stock merger. Upon completion of the transaction, the combined company plans to operate under the name Serapha Bio, Inc. and is expected to trade on Nasdaq under the ticker symbol “AATD”. In support of the proposed merger, Serapha has secured commitments for pre-closing private investments of approximately $230 million from a syndicate of investors.
Read the full article: Boundless Bio and Serapha Bio Announce Merger Agreement and $230M Concurrent Private Placement //
Source: https://www.globenewswire.com/news-release/2026/06/23/3315846/0/en/boundless-bio-and-serapha-bio-announce-merger-agreement-and-230-million-concurrent-private-placement.html?_gl=1*107nrcj*_up*MQ..*_ga*MjI2NjYzMjc3LjE3ODIyMTc5MTA.*_ga_B6167QB2TF*czE3ODIyMTc5MDkkbzEkZzAkdDE3ODIyMTc5MDkkajYwJGwwJGgxMTM4MDk1MDcz*_ga_ERWPGTJ5X8*czE3ODIyMTc5MTAkbzEkZzAkdDE3ODIyMTc5MTAkajYwJGwwJGgw